Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone ...

The effort by the Center for Regenerative Medicine of Boston University, Boston Medical Center, and GSK aims to find new ...

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...

including idiopathic pulmonary fibrosis (IPF). “These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung ...

Under the terms of the agreement, Surrozen will provide antibody discovery services for a period of up to two years. TCGFB will own all TGF-β product related intellectual property. In exchange for ...

Columnist Sam Kirton is doing a service for him and his family's future generations by sharing his research on the family ...

For patients who received SBRT, the analysis included 90-day mortality as well as new-onset or treatment-induced toxicity, ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...